• CytoResc Trial
• Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study
• ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines
•  N = 40–50 ‘CytoSorb’
• N = 40–50 standard care
• Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)